Cessation of Ciprofloxacin Prophylaxis in Hemato-Oncology Patients
Louise Caldwell, Anjaneya Bapat, Lydia N. Drumright, Jonathan Lambourne, Fergus G Jimenez-England, James Aries, Lydia Eccersley, Simon Hallam, Silvia Montoto, Heather Oakervee, John C. Riches, Samir Agrawal
Abstract
To the Editor-We read with interest the article by Satlin et al In September 2019, our tertiary stem-cell transplant center in London discontinued routine use of fluoroquinolone (ciprofloxacin) prophylaxis for inpatients anticipated to have prolonged neutropenia. The factors that prompted this change in practice were high rates of ciprofloxacin resistance in gram-negative bloodstream infections (BSIs) both locally (59%, and 75% in extended-spectrum beta-lactamase [ESBL]-producing organisms) and nationally [3], the detrimental impact of broad-spectrum antibiotics on the microbiome in transplant patients